ketamine | CARLAT PUBLISHING

CARLAT WEBINAR

Carlat Psychiatry News - Stimulant Fraud • Oral Ketamine • E-Cigarettes • Benzo Tapering • CBD

September 17, 2024

Chris Aiken, MD, Greg Malzberg, MD, and Kellie Newsome, PMHNP

0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.

Ketamine Assisted Therapy Part III

July 8, 2024

Chris Aiken, MD, Kellie Newsome, PMHNP, and Kyle T. Greenway, MD, MSc

Kyle Greenway developed the Montreal Model to pair ketamine with psychotherapy. In this 3-part series, he shows us how to do it.

Ketamine Assisted Therapy Part II

July 1, 2024

Kellie Newsome, PMHNP, Chris Aiken, MD, and Kyle T. Greenway, MD, MSc

Kyle Greenway developed the Montreal Model to pair ketamine with psychotherapy. In this 3-part series, he shows us how to do it.

Ketamine Assisted Therapy Part I

June 24, 2024

Chris Aiken, MD, Kellie Newsome, PMHNP, and Kyle T. Greenway, MD, MSc

Kyle Greenway developed the Montreal Model to pair ketamine with psychotherapy. In this 3-part series, he shows us how to do it.

Expert Q&A

Ketamine-Assisted Therapy

June 1, 2024

Kyle T. Greenway, MD, MSc

Kyle T. Greenway, MD, MSc.

Assistant Professor of Psychiatry at McGill University. Director of the ketamine-assisted therapy program at Jewish General Hospital, Montreal, Canada.

Dr. Greenway has no financial relationships with companies related to this material.

A psychotherapeutic plan to make ketamine’s benefits last.

Clinical Update

Off-Label Strategies for Common Psychiatric Conditions

June 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Five disorders where going off-label has advantages over the FDA-approved route.

Research Update

Ketamine Fails to Outperform Placebo for Depression in Patients Under Anesthesia

May 1, 2024

Awais Aftab, MD.

Awais Aftab, MD. Dr. Aftab has no financial relationships with companies related to this material.

A look whether administering ketamine during general anesthesia changes its ability to treat depression.

Expert Q&A

Ketamine Use and Misuse

April 1, 2024

Keith A. Trujillo, PhD

Keith A. Trujillo, PhD.

Emeritus Professor of Psychology, California State University, San Marcos, CA.

Dr. Trujillo has no financial relationships with companies related to this material.

Ketamine and esketamine represent some of the most powerful rapid-acting agents in our armamentarium of treatments for depression. However, ketamine is also an addictive substance, and there is emerging evidence that the widespread use of ketamine may be causing more patient harms than we were previously aware of. Here, Dr. Trujillo discusses how to use ketamine safely in clinical practice.

Research Update

Cognitive Training Extends Ketamine’s Benefits

February 1, 2024

Avneet Soin, MD.

Avneet Soin, MD. Dr. Soin has no financial relationships with companies related to this material.

A positive psychology program hopes to boost the short-lived benefits of ketamine infusion.

CARLAT WEBINAR

Ketamine and the Evolving Psychopharmacologic Pipeline for Depression

December 8, 2023

Robert C. Meisner, MD

0.50 CME Credits. Robert Meisner, MD, explores the latest developments in psychiatric treatment with ketamine and esketamine, including their differences and emerging insights for clinicians.